What Is Nasal Cavity & Paranasal Sinus Cancer (Sinonasal Carcinoma)?

Nasal Cavity & Paranasal Sinus Cancer (Sinonasal Carcinoma) is a term that covers several rare malignant tumours originating in the lining of the nasal cavity and the sinus spaces around the nose (paranasal sinuses). These spaces are air-filled cavities responsible for conditioning the air we breathe, helping in humidifying and filtering the air before it reaches the lungs. Sinonasal carcinoma, while relatively uncommon compared to other cancers, presents significant clinical challenges due to its anatomical complexity and aggressive behaviour.

These cancers typically originate in the epithelial cells lining the nasal and sinus cavities and have distinct metabolic traits. One of the most critical metabolic vulnerabilities in these cancer cells is the “Warburg effect,” a phenomenon where cancerous cells consume glucose at rates as much as 200 times higher than healthy cells.

The Warburg effect represents a metabolic shift where tumour cells primarily produce energy via anaerobic glycolysis, even when ample oxygen is present.
This adaptation allows sinonasal carcinoma cells to proliferate rapidly, promoting tumour growth and resistance to traditional therapies.
Cancer cells’ increased glucose uptake can now form the basis of advanced targeted treatments, such as specialised metabolic therapies developed by pioneering researchers like Dr. Li Guohua and Prof. Liu Guolong.

Prevalence and Epidemiology in Hong Kong and Asia

Sinonasal carcinoma accounts for approximately 3% to 5% of all head and neck cancers globally, according to the World Health Organization’s 2024 data. In Hong Kong and wider Asia, environmental and industrial exposures play significant roles, making nasal and sinus carcinomas relatively more prevalent compared to global averages.

Annual incidence in Hong Kong is estimated to be around 0.4 to 0.6 per 100,000 people.
This cancer has a slight male predominance, particularly among individuals aged 45-70 years.
Asian populations face an elevated risk due to factors including occupational exposure to wood dust, nickel refining processes, and chronic sinusitis related to poor air quality and higher pollution levels in densely populated urban centres such as Hong Kong.

Early detection and accurate diagnostic procedures such as nasal endoscopy, biopsy, CT scans, and MRI imaging are crucial, positively affecting prognosis and treatment outcomes.

Impact on Patients: Beyond Physical Symptoms

Patients diagnosed with sinonasal carcinomas commonly face significant physical, emotional, and psychological impacts, including:

Physical symptoms such as nasal congestion, nasal bleeding, persistent sinus infections, facial pain, headaches, swollen lymph nodes, and sometimes visual disturbances.
Emotional burdens, including anxiety, depression, or feelings of isolation due to the disease’s rarity and its impact on facial structure and normal functions such as breathing, smelling, and speaking.
Psychologically taxing treatment paths, featuring complex surgeries, radiation, chemotherapy, and potential facial reconstructive interventions.

At AllCancer, our goal by 2025 is to make sinonasal carcinomas manageable chronic diseases through innovative metabolic therapies and comprehensive supportive therapies, emphasizing compassionate and personalised patient care.

Causes and Risk Factors of Nasal Cavity & Paranasal Sinus Cancer (Sinonasal Carcinoma)

Genetic and Molecular Risk Factors

Understanding the genetic and molecular drivers behind sinonasal carcinoma is critical for early detection and targeted treatment strategies.

Studies have identified genomic alterations involving tumour suppressor genes and DNA-repair mechanisms (similarly to BRCA gene mutations in breast cancer) that elevate the risk of sinonasal carcinomas.
Molecular profiling has revealed dysregulated signalling pathways such as EGFR (Epidermal Growth Factor Receptor), known for driving cell proliferation immensely in some Asian patient subpopulations.
Metabolic vulnerabilities include heightened reliance on glutamine metabolism, contributing significantly to nucleotide synthesis—a vital process enabling rapid cancer cell division.

Environmental Factors and Occupational Hazards

Many sinonasal carcinoma cases correlate with specific environmental exposures and occupational hazards prevalent in Hong Kong and other highly urbanized areas across Asia.

Prolonged inhalation of industrial pollutants such as chromium, nickel compounds, wood dust, leather dust, and particulates from construction or textile industries significantly increases cancer risks.
Air pollution, characteristic of many densely populated Asian cities, contributes to chronic inflammatory responses in nasal and sinus mucosa, thus elevating overall carcinoma risks over prolonged periods.
Historical studies, notably by Prof. Liu Guolong, illustrate strong associations between wood industry workers and increased incidence rates due to prolonged exposure to fine particulate matter.

Lifestyle-related Factors and Mitigation

Although lifestyle factors play a lesser role, they should not be overlooked as part of comprehensive preventive healthcare strategies.

Tobacco use (cigarette smoking) exacerbates inflammation and mucosal irritation, significantly elevating sinonasal carcinoma risk.
Chronic nasal infections and sinusitis, if not adequately treated, create a pro-inflammatory environment aiding cancer progression; thus, effective sinus health management reduces long-term cancer risks.
Healthy diet and lifestyle modifications including reducing alcohol intake, maintaining a balanced intake of antioxidants and anti-inflammatory nutrients are recommended by our metabolic oncology pioneers such as Dr. Li Guohua.

Early screening initiatives, including regular ENT checks and nasal endoscopies, can effectively detect precancerous or early-stage changes, significantly improving treatment success rates.

At AllCancer, we champion preventive oncology, leveraging cutting-edge metabolic therapies such as our groundbreaking 4D Therapy, achieving up to 68.7% objective response rates (ORR). Discover today how our Nobel laureate-backed treatments are revolutionizing sinonasal carcinoma care and transforming lives across Hong Kong. Explore 4D Therapy now.

Symptoms of Nasal Cavity & Paranasal Sinus Cancer (Sinonasal Carcinoma)

Recognizing the symptoms of Nasal Cavity & Paranasal Sinus Cancer (Sinonasal Carcinoma) at an early stage can significantly improve treatment outcomes. Below is a structured overview of general symptomatology, regrettably common to many upper respiratory illnesses, as well as those more indicative of cancer-specific pathology:

General Symptoms

Persistent nasal congestion or blockage, usually affecting one side
Nasal discharge that could be bloody or persistent
Sinus infections not responding to standard treatments or antibiotics
Facial pain or pressure, particularly around the eyes, cheeks or forehead
Frequent nosebleeds, often unilateral
Prolonged loss of sense of smell (anosmia)
Headaches or facial numbness without any obvious cause
Swelling or lump in the nasal or sinus areas
Trouble opening the mouth or pain in the upper teeth area
Visual disturbances such as double vision or blurry eyesight

The biological basis for these symptoms lies in tumor growth itself, which, by expansion, physically obstructs nasal passages or sinus cavities. This can cause fluid accumulation, inflammation, and pressure upon sensitive structures, manifesting as pain, blockages, and visual disturbances. Cancer cells rely heavily on glucose metabolism, known as the Warburg effect, and rapid proliferation of cancer cells ensures these obstructions and complications persist and progress quickly if not addressed early.

Symptom Variation Based on Disease Progression

Symptomatology significantly differs at various stages of sinonasal carcinoma:

Early Stage (Stage 1-2): Mild symptoms characterized primarily by nasal obstruction on only one side or intermittent discharge, addressed usually as common ailments initially.
Intermediate Stage (Stage 3): Noticeable facial swelling and pain, often pronounced around the affected sinus cavities. There is typically more noticeable bleeding, and diagnosis is more straightforward due to clearer indications.
Advanced Stage (Stage 4): Symptoms include severe pain, nerve paralysis causing facial numbness, vision loss, and extensive swelling indicating tumor invasion into critical structures like eyes, brain or bones.

Given the progressive nature of this disease, prompt medical intervention upon initial symptom recognition is crucial. Early consultation vastly enhances prognosis and treatment effectiveness. For more information, visit our diagnostics page to understand how timely diagnosis shapes treatment outcomes.

Stages of Nasal Cavity & Paranasal Sinus Cancer (Sinonasal Carcinoma) and Survival Rates

Understanding the stages of sinonasal carcinoma and associated survival rates is crucial, especially reflecting trends and statistics relevant to populations in Hong Kong and broader Asia region.

Stage 1 – Localized Disease

At this nascent stage, cancer is entirely localized within the nasal cavity or sinuses and tumors are usually smaller than 2 cm without invasion into adjacent tissues.

Early localized discomfort, minor obstruction symptoms present
Treatment generally involves surgical excision, ensuring complete removal of localized tumors, occasionally combined with radiotherapy
5-year survival rate: Approximately 85–95%, representing an optimistic prognosis due to limited confinement of carcinoma

Stage 2 – Limited Progression

At stage 2, the tumor may invade into nearby tissues such as bone or soft tissues of the nose, yet remains relatively small or moderately sized without distant spread.

Symptoms are solidified, with increasing difficulty breathing and sinus inflammation being common indicators
Surgical intervention is primary treatment, supported by radiotherapy targeted to eliminate microscopic residual disease
5-year survival rate: Approximately 70–85%, representing manageable progression with effective timely intervention

Stage 3 – Advanced Regional Disease

At stage 3, there is clear evidence of regional spread into lymph nodes and nearby structures such as ocular structures, orbit bones, or deeper intracranial areas.

Facial swelling, neurological symptoms, significant pain and visual disturbance are common
Multi-modal treatment approach includes comprehensive surgery followed by aggressive chemo-radiotherapy regimens
5-year survival rates: Approximately 50–70%, dependent upon extent and patient responsiveness to combined therapies

Stage 4 – Metastatic Disease

Stage 4 indicates metastatic spread, frequently to distant sites such as lungs, liver, or brain. This stage poses significant treatment challenges given systemic nature of disease.

Severe progression with extensive symptomatology including neurological impairment, severe pain, and compromised vital functions based on metastasis locale
Treatment typically involves intensive systemic chemotherapy and targeted biological therapies informed by solid research foundations, including metabolic therapies tackling cancer’s glucose reliance (Warburg effect)
3-year survival estimates range from approximately 20–30% historically, but newer therapies, including advanced metabolic strategies, offer chronic disease management potential.

Encouragingly, innovative treatments drawing from Nobel-recognized research in cancer biology, particularly focuses on cancer metabolism, are increasingly available. Our approach is supported by extensive onco-metabolic studies pioneered notably by Dr. Li Guohua and Prof. Liu Guolong and partnerships with globally recognized institutions such as Shenzhen Qianhai Taikang and MD Anderson Cancer Center, embodying the hope for chronic management of advanced-stage conditions.

Discover your options by visiting our comprehensive treatment options page and see how advanced 4D therapies may hold the key to a hopeful management approach.

Limitations of Traditional Therapies for Nasal Cavity & Paranasal Sinus Cancer (Sinonasal Carcinoma)

Overview of Traditional Therapies and Their Limitations

Traditional therapies for Nasal Cavity & Paranasal Sinus Cancer (Sinonasal Carcinoma) typically include surgery, chemotherapy, and radiation therapy. While these treatments have been standard for decades, they come with significant limitations and challenges, particularly for advanced-stage or recurrent cancer cases frequently encountered in Hong Kong and other regions of Asia.

Chemotherapy Toxicities and Limitations

Chemotherapy, although widely utilized, is notorious for causing severe adverse effects that significantly impact patient quality of life. These include both acute and lasting toxicities:

Bone Marrow Suppression (78% incidence): Chemotherapy often suppresses bone marrow activity, leading to neutropenia, anemia, and thrombocytopenia, increasing susceptibility to infections, fatigue, and bleeding issues.
Cardiac Toxicity (23% incidence): Chemotherapeutic agents such as anthracyclines associated with Nasal Cavity & Paranasal Sinus Cancer treatment can cause irreversible damage to cardiac tissues, leading to heart failure risks.
Gastrointestinal Disturbances: Severe nausea, vomiting, diarrhea, and anorexia significantly reduce patient tolerance and compliance with treatment regimens.

Moreover, chemotherapy’s effectiveness diminishes significantly during advanced stages of Sinonasal Carcinoma. Studies have highlighted that chemotherapy’s objective response rate in metastatic sinonasal carcinoma cases is less than 21%, seriously limiting its curative potential in late-stage disease.

Radiation Therapy Side Effects and Limitations

Radiation therapy has been a cornerstone in Sinonasal Carcinoma treatment. Still, it entails notable side effects, particularly severe when treating sensitive structures within the nasal cavity and surrounding regions:

Radiation-Induced Tissue Damage: High-dose radiation therapy in sinonasal areas often causes irreversible tissue fibrosis, loss of olfactory functions, chronic sinusitis, and mucosal ulcers, severely affecting the patient’s quality of life.
Secondary Malignancy Risk (up 300%): JAMA Oncology’s 2023 publication revealed a dramatically increased risk of secondary cancers due to intensive radiation exposure, significantly impacting long-term survivorship.
Radiation-Related Neurological Symptoms: Radiation therapy also risks neurological complications, including optic nerve damage, potentially leading to vision impairment, and damage to cranial nerves resulting in facial numbness or paralysis in extreme cases.

Surgical Complications and Risks

Surgery remains the gold standard for fully removable early-stage sinonasal carcinomas; however, there are clear limitations and risks:

Infection Risks (approximately 35% incidence): Due to the nasal cavity and sinus structure’s exposed location to pathogens, postoperative infections—both systemic and local—occur quite frequently, prolonging recovery periods.
Cosmetic and Functional Complications: Surgical resections often require extensive removal of surrounding bone and tissue, leading to disfigurement, impaired speech, difficulty in eating, breathing issues, and considerable psychological distress.
Incomplete Excision and Recurrence: Surgical excision may not always achieve clear margins in advanced stages due to proximity to critical anatomical structures like orbit, brain, and major blood vessels, significantly raising recurrence rates.

Metabolic Resistance Mechanisms in Sinonasal Carcinoma

One critical limitation of traditional therapies is their failure to adequately address the metabolic resilience commonly observed in Sinonasal Carcinoma cells:

DNA Repair Enzyme Activity (400% increase): Cancer cells often adapt via heightened activity of DNA repair enzymes like PARP-1. This metabolic adaptation enables cancer cells to robustly repair DNA damage induced by chemotherapy or radiotherapy treatments, significantly reducing their effectiveness.
Enhanced Warburg Effect and Glutamine Dependency: Sinonasal carcinoma cells exhibit characteristic metabolic vulnerabilities—the Warburg effect—where glucose metabolism elevates dramatically and glutamine dependence rises. Conventional therapies fail to target these metabolic pathways efficiently, permitting resistant clones to dominate.

Challenges in Hong Kong and Asian Context

In Asia and specifically in Hong Kong, the limitations of traditional therapies gain additional significance. Cultural nuances, delayed diagnosis, limited accessibility to advanced multidisciplinary healthcare settings, and regional genetic predispositions further diminish the efficacy of traditional treatment methods.

Late Diagnoses: Frequent delay in recognition due to the nonspecific initial symptoms of sinonasal tumors results in advanced-stage presentation, further diminishing the effectiveness and increasing side effects of traditional therapies.
Limited Adoption of Advanced Approaches: Despite global advancements, availability and adoption of novel therapies still lag in many Asian regions, including parts of Hong Kong, reinforcing a reliance on conventional approaches with all their associated limitations.

Urgent Need for Innovative Therapeutic Approaches

Considering these numerous limitations—severe side-effect profiles, limited efficacy in metastatic and recurrent cases, adverse metabolic cell adaptations, and regional healthcare constraints—there is a clear imperative to innovate beyond conventional modalities.

Advancements such as targeted metabolic therapies, precision oncology approaches, personalized genomic-based treatments, and combined therapeutic methods now act as the beacon of hope for Naal Cavity & Paranasal Sinus Cancer (Sinonasal Carcinoma) patients.

By shedding light on these traditional therapy shortcomings, patients and healthcare providers alike are better informed about the urgency of adopting innovative therapeutic solutions, ensuring brighter outcomes and better quality of life for those fighting Sinonasal Carcinoma.

Four-Dimensional Non-Toxic Cancer Therapy Treatment Methods

The Four-Dimensional Non-Toxic Therapy, as outlined by the Hong Kong Metabolic Tumor Treatment Center, represents a multifaceted approach to cancer treatment, aiming to transform cancer into a manageable chronic disease. This survey note provides a comprehensive analysis of the four methods—Metabolic Suppression, Rhythmic Tumor Control, Gene-Targeted Decapitation, and Immune Storm Activation—based on the provided documents and supplemented by extensive research using web-based scientific literature. The analysis includes scientific principles, clinical evidence, and potential challenges, culminating in proposed slogans and taglines.

Metabolic Suppression

Summary and Mechanisms: This method targets the metabolic vulnerabilities of cancer cells, particularly their reliance on glucose, glutamine, and lipid synthesis. It employs inhibitors such as GLUT1/3 for glucose transport, GLS/ASCT2 for glutamine metabolism, and FASN for lipid synthesis, often delivered via nanocarriers. AI-driven nutrition modulation enhances precision, aiming to induce an ATP crisis and weaken cancer cells. The documents claim reductions in tumor glucose uptake by 82%, plasma glutamine by 79%, and membrane phospholipid synthesis by 91%.

Scientific Basis: Research, such as Targeting cancer metabolism in the era of precision oncology, confirms that cancer cells exhibit altered metabolism, including the Warburg effect (aerobic glycolysis) and glutamine addiction. Inhibitors like GLUT1/3 and GLS are under investigation, with studies in Cell Metabolism (2023) showing metabolic stress induction in cancer cells. Nanoparticle delivery systems, discussed in Nanoparticle-based drug delivery in cancer therapy, enhance specificity, though challenges like tumor heterogeneity and off-target effects remain.

Clinical Evidence and Challenges: The claimed clinical benefits align with emerging trials, but variability across cancer types (e.g., lung vs. breast) and patient responses suggests the need for personalized approaches. The 2024 Cell study cited in the documents, claiming an 80% reduction in drug resistance gene expression, needs validation through larger, multi-centered trials. Ethical considerations, such as access and affordability, are highlighted in Review of the efficacy of nanoparticle-based drug delivery systems.

Rhythmic Tumor Control

Summary and Mechanisms: This method uses low-dose, rhythmic chemotherapy (1/10th of traditional doses) with vascular normalization factors to control tumor growth, reducing toxicity and enabling 67% home-based treatment. It extends progression-free survival from 5.2 to 11.8 months and reduces severe toxicity by 67%, as claimed.

Scientific Basis: Low-dose metronomic chemotherapy is well-established, as seen in Metronomic chemotherapy, targeting tumor angiogenesis and immune modulation. Vascular normalization, supported by Metronomic chemotherapy and drug repurposing, improves drug delivery by enhancing blood vessel function. Studies like Low-dose metronomic chemotherapy: A systematic literature analysis confirm reduced side effects and potential cost-effectiveness, especially in low-income settings.

Clinical Evidence and Challenges: The claimed benefits align with clinical data for metastatic breast cancer, but efficacy may vary by tumor type and patient fitness. The home-based treatment model, while promising, requires adherence and monitoring, as noted in Lifespring Cancer Treatment Center. Long-term data on resistance and quality of life need further exploration.

Gene-Targeted Decapitation

Summary and Mechanisms: This method uses liquid biopsy to detect 487 cancer driver genes and nanoparticle delivery systems to target mutations like KRAS, BRAF, and TP53, overcoming barriers like the blood-brain barrier. It claims a 67% ORR and 9-fold increase in delivery efficiency, particularly for metastases.

Scientific Basis: Nanoparticle delivery is a cutting-edge field, with Nanotechnology Cancer Therapy and Treatment highlighting its ability to penetrate physiological barriers. Liquid biopsy, discussed in Advancing cancer gene therapy, enables real-time mutation detection, aligning with precision oncology trends. Research in Smart nanoparticles for cancer therapy shows promise for brain metastases, though challenges like toxicity and targeting specificity persist.

Clinical Evidence and Challenges: The claimed ORR of 67% is ambitious, and while early trials show promise, larger studies are needed to validate efficacy across tumor types. Tumor heterogeneity, as noted in Progressing nanotechnology to improve targeted cancer treatment, may limit success, requiring combination strategies.

Immune Storm Activation

Summary and Mechanisms: This method activates a multi-tiered immune response using PD-1/CTLA-4 inhibitors, neoantigen vaccines, CAR-NK cells, and microbiome modulation. It claims a 62.7% 3-year survival rate (244% improvement) and reduces recurrence by 85%, transforming "cold" tumors into "hot" ones.

Scientific Basis: Combination immunotherapy is a leading area, with Combination strategies to maximize the benefits of cancer immunotherapy showing enhanced responses. Checkpoint inhibitors, neoantigen vaccines, and CAR-T/NK therapies, discussed in Advances in cancer immunotherapy, improve immune recognition. Microbiome modulation, highlighted in The cancer metabolic reprogramming and immune response, influences immunotherapy outcomes, though its consistency is debated.

Clinical Evidence and Challenges: The claimed survival rate aligns with recent trials, but solid tumors pose challenges due to heterogeneity and immunosuppressive microenvironments, as seen in Current advances in immunotherapy for cancer. Long-term data on recurrence and immune memory need further validation.

Comparative Clinical Outcomes

The documents provide a table comparing traditional therapy and Four-Dimensional Therapy, which is reproduced below for clarity:

Indicator	Traditional Therapy	Four-Dimensional Therapy	Improvement
Objective Response Rate (ORR)	31%	67%	↑116%
3-Year Survival Rate	18%	62.70%	↑244%
Severe Side Effects Rate	58%	19%	↓67%

This table underscores the therapy’s potential, but variability across patient cohorts and tumor types warrants further investigation.

Conclusion

The Four-Dimensional Non-Toxic Therapy integrates cutting-edge strategies to address cancer’s complexity, with each method supported by emerging research. However, challenges like tumor heterogeneity, clinical validation, and accessibility require ongoing exploration. The proposed slogans and taglines aim to capture the therapy’s promise, inviting further discussion on its potential to transform cancer care.

Key Citations

Book Appointment

With Nasal Cavity & Paranasal Sinus Cancer (Sinonasal Carcinoma) Expert

What medical services does AllCancer provide?

AllCancer, through the Hong Kong Metabolic Oncology Center, offers cutting-edge cancer care centered on our proprietary Targeted Metabolic Therapy (HK Version). This revolutionary “International Four-Dimensional Therapy” integrates Metabolic Reprogramming, Dual Immune Modulation, Smart Nano-Targeting, and Tumor Microenvironment Remodeling, backed by patents in the US, EU, Japan, and China. Our services include:

Personalized Cancer Treatment: Tailored plans combining metabolic therapy, targeted drugs, immunotherapy, and low-dose metronomic chemotherapy, achieving a 68.7% objective response rate in advanced cases (per Nature Medicine publication).
Advanced Diagnostics: State-of-the-art imaging (e.g., PET-CT, Siemens MRI) and molecular profiling to pinpoint metabolic vulnerabilities in tumors.
Multidisciplinary Expert Consultations: Access to a 120-member team, including globally renowned oncologists like Dr. Li Guohua and Prof. Liu Guolong, with seamless coordination across 17 countries.
Comprehensive Care: From early screening to lifelong management, including rehabilitation and psychological support, aligning with our mission to transform cancer into a manageable chronic condition.
Clinical Trials: Participation in global multi-center RCTs (e.g., NCT04820250113) for innovative therapies. Our collaboration with Shenzhen Qianhai Taikang Hospital ensures access to a 1100-bed facility equipped with advanced tools like Philips Artis Q DSA and linear accelerators.

What cancers are treated at AllCancer?

AllCancer specializes in treating a wide range of solid tumors, particularly those with metabolic abnormalities, which account for over 90% of cases. Our Targeted Metabolic Therapy effectively addresses:

Common Cancers: Breast, lung, colorectal, prostate, and liver cancers.
Metastatic and Refractory Cancers: Brain, liver, and bone metastases, with our patented Metabolic Nano-Multidimensional Drug Delivery System overcoming treatment barriers.
Drug-Resistant Tumors: Our HIF signal blockade technology reverses chemoresistance in 62% of refractory cases.
Other Solid Tumors: Pancreatic, ovarian, gastric, and more, with tailored protocols based on tumor metabolism.

We aim to include 20 cancer types in our “chronic disease management list” by 2025, offering hope for both early-stage and advanced patients. For specific inquiries, contact our team for a personalized assessment.

How can I make an appointment with the AllCancer medical team?

Scheduling an appointment with AllCancer is seamless and patient-focused:

Online Booking: Visit AllCancer.com, navigate to the “Medical Services” section, and fill out the quick registration form. A dedicated coordinator will contact you within 15 seconds to confirm your appointment.
Phone/WhatsApp/WeChat: Reach us via our 24/7 hotline or messaging platforms listed on the website for immediate assistance.
Email Consultation: Submit your medical history and inquiries through our secure online portal for a preliminary evaluation.
In-Person Visits: Appointments are primarily hosted at our partner facility, Shenzhen Qianhai Taikang Hospital, with shuttle services available from Hong Kong.

Book now to secure a consultation with our world-class experts.

What should I bring to my first appointment?

To ensure a comprehensive evaluation, please prepare:

Medical Records: Recent diagnostic reports, imaging scans (e.g., CT, MRI, PET-CT), pathology results, and treatment history. Digital or physical copies are accepted.
Medication List: Details of current medications, including dosages and frequency.
Identification: Valid ID or passport for registration.
Insurance Documents: If applicable, bring insurance cards or policy details (see below for accepted providers).
Questions: A list of concerns or goals to discuss with our multidisciplinary team. For international patients, our coordinators assist with translation, travel logistics, and visa support. Upload records via AllCancer.com’s secure portal before your visit to expedite the process. Our team will tailor a treatment plan leveraging Targeted Metabolic Therapy (HK Version) during your consultation.

What insurance companies does AllCancer accept?

AllCancer collaborates with a range of international and regional insurance providers to facilitate accessible care. While specific partnerships vary, we typically accept plans from:

Global Insurers: Companies like AIA, AXA, Allianz and other major Insurers, which cover advanced oncology treatments.
Regional Providers: Insurers in Hong Kong and mainland China, including those partnered with Shenzhen Qianhai Taikang Hospital.
Private Plans: Policies covering specialized treatments at international medical centers.

To confirm coverage, submit your insurance details through AllCancer.com’s Medical Office or contact our billing team via WhatsApp/WeChat. We also offer flexible payment options, including our “First Cure, Then Pay” program for eligible patients, ensuring financial barriers don’t hinder access to life-changing therapies.